USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Otsuka Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 273 granted patents across 73 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

273

Total patents granted

CPC technology areas

14.6

Avg claims per patent

-8%

5-year filing velocity

The verdict

Otsuka holds 273 US patents across 73 technology areas, rank #1,526 of 50,000 tracked assignees.

#1,526
of 50,000 US assignees by volume: Top 2%
by Innovation Score (62.4/100): 14.6
avg claims per patent: -8%
filing velocity, last 5 yrs

Portfolio overview

Otsuka Pharmaceutical Co., Ltd. has been granted 273 US utility patents between 2015 and 2025, placing Otsuka Pharmaceutical Co., Ltd. at rank #1,526 across all assignees tracked by PlainPatent. This portfolio spans 73 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Otsuka Pharmaceutical Co., Ltd. is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Otsuka sits between Denso TEN Limited (273 patents, rank #1,522) and William Marsh Rice University (273 patents, rank #1,530) - the closest US assignees by grant volume. The composite Innovation Score of 62.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 131 grants, compared with 142 in the 2015–2019 window, a -8% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Otsuka Pharmaceutical Co., Ltd.'s 14.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 73 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Otsuka Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.

Denso TEN

273
DH Development PTE

273
Nabtesco

273
OMYA International

273
Pearson Education

273
Roche Sequencing…

273
Valeo Schalter UN…

273
William Marsh Ric…

273
Otsuka Pharmaceut… ◀

273

What this shows Otsuka holds 273 patents at rank #1,526, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Otsuka

By rank, the assignees closest to #1,526 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Otsuka's primary technology class.

Otsuka's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

62 Top 2% higher than 98% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Otsuka Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	68	24.9%
2016	25	9.2%
2017	24	8.8%
2018	9	3.3%
2019	16	5.9%
2020	18	6.6%
2021	23	8.4%
2022	30	11.0%
2023	24	8.8%
2024	25	9.2%
2025	11	4.0%

Which technologies does Otsuka Pharmaceutical Co., Ltd. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 171

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 153

C07D - HETEROCYCLIC COMPOUNDS 63

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 31

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 30

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 23

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 18

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 18

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 17

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 15

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 14

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 13

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 12

B01L - CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE 11

H04B - TRANSMISSION 10

Top 15 of 73 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,526

Across all tracked assignees

Innovation Score

62.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Otsuka Pharmaceutical Co., Ltd. hold?

Otsuka Pharmaceutical Co., Ltd. holds 273 US granted patents filed between 2015 and 2025, spanning 73 technology areas.

What is Otsuka Pharmaceutical Co., Ltd.'s Innovation Score?

Otsuka Pharmaceutical Co., Ltd. has an Innovation Score of 62.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Otsuka Pharmaceutical Co., Ltd. focus on?

Otsuka Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 171 patents. The company has filed patents in 73 CPC subclasses total.

Is Otsuka Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?

Otsuka Pharmaceutical Co., Ltd.'s recent filing velocity is -8% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Otsuka Pharmaceutical Co., Ltd.'s patents?

Otsuka Pharmaceutical Co., Ltd.'s patents average 14.6 claims each. This falls within the standard range, providing solid legal coverage.

How is the Otsuka Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Otsuka's 273 grants land it in the top 2% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Otsuka ranks #1,526 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.